ABSTRACT
ObjectiveTo investigate the incidence and influencing factors of postpartum depression and anxiety in Urumqi during the coronavirus disease （COVID-19） epidemic period in 2020. MethodsResearch subjects were the parturients who underwent postpartum health checkups in a third class hospital in Urumqi from January 2020 to December 2020. The maternal socio demographic and obstetric information were collected， and PHQ-9 and GAD-7 scales were used for screening of PPD and PPA. Calcaneal bone mineral density of the parturients was measured by French Pegasus ultrasonic bone densitometer. After univariate analysis of the related influencing factors of PPD and PPA， multivariate binary logistic regression analysis was used to explore the relationship between mental disorders and various influencing factors. ResultsA total of 2 490 puerpera participated in the survey. The incidences of PPD and PPA in 2020 were 13.4 % and 10.8 %， respectively. Six factors with statistical differences after univariate analysis were included in multivariate binary logistic regression analysis. The final results suggested that age over 35 （OR=1.707，95%CI：1.142‒2.551）， unemployment （OR=1.478，95%CI：1.003‒2.205）， multipara（OR=1.340，95%CI：1.037‒1.733）， bone loss and osteoporosis （OR=1.434，95%CI： 1.076‒1.910） were the risk factors of PPD， while breastfeeding （OR=0.466，95%CI： 0.301‒0.721） was a protective factor. Ages between 18‒24 （OR=1.559，95%CI：1.282‒3.097） and cesarean section （OR=1.433，95%CI： 1.105‒1.859） were the risk factors of PPA， while ages between 30‒34 years old （OR=0.524，95%CI： 0.332‒0.827）， occupation as medical staff （OR=0.282，95%CI： 0.807‒0.919）， breastfeeding （OR=0.530，95%CI： 0.330‒0.850） were protective factors. ConclusionIncidences of PPD and PPA are in middle-low levels during COVID-19 epidemic period. Age， occupation， delivery mode， delivery times， feeding pattern and bone mineral density are the influencing factors. Screen coverage of PPD and PPA in special period should be strengthened， and measures should be taken to reduce the risk.
ABSTRACT
Atherosclerosis(AS) is the basic pathological process of many cardiovascular and cerebrovascular diseases. Particularly, the rupture of vulnerable plaques is a major cause of disability and death among middle-aged and elderly people. It's crucial to find out some reliable serummarkers for diagnosis, treatment and prognosis of AS. This study aims to summarize some newly reported miRNAs which can control the development of AS by regulating the biological function of endothelial cells, smooth muscle cells and macrophages.We also enumerated some target genes and signal pathways that they may act on, and thus provide some new ideas for the treatment of AS and to provide theoretical basis for finding serum biomarkers which can evaluate the occurrence and stability of AS plaque.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of montelukast combined with moxifloxacin in the treatment of cough of acute bacterial bronchitis. METHODS:A total of 139 cases of cough of acute bacterial bronchitis selected from out-patient department of Ningbo Yinzhou District Qianhu Hospital during Jan.-Dec. 2016 were divided into control group(69 cases) and observation group(70 cases)according to random number table. Control group was given Moxifloxacin hydrochloride tab-lets 0.4 g,po,qd;observation group was additionally given Montelukast sodium tablets 10 mg,po,once every night,on the basis of control group. Both groups were treated for 6 d. Cough symptom scores,peripheral blood WBC and CRP contents were compared between 2 groups before and after treatment. Clinical efficacies,the occurrence of ADR and clinical outcome were ob-served in 2 groups. RESULTS:Before treatment,there was no statistical significance in cough symptom scores,peripheral blood WBC or CRP contents between 2 groups(P>0.05). Compared to before treatment,cough symptom scores,peripheral blood WBC and CRP contents of 2 groups were decreased significantly after treatment,and the cough symptom score of observa-tion group after 3 d of treatment was significantly lower than that of control group at the same time,with statistical significance (P<0.05). There was no statistical significance in above indexes between 2 groups after 6 d of treatment(P>0.05). Cure rate of observation group was 64.29%,which was significantly higher than 44.93% of control group,with statistical significance (P<0.05). Response rates of observation group and control group were 97.14% and 97.10%,there was no statistical signifi-cance(P>0.05). No ADR was found in 2 groups during treatment,and good clinical outcome was obtained. CONCLUSIONS:Montlukast combined with moxifloxacin not only relieve cough symptom and inflammation,but also improve cure rate significantly with good safety.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of montelukast combined with moxifloxacin in the treatment of cough of acute bacterial bronchitis. METHODS:A total of 139 cases of cough of acute bacterial bronchitis selected from out-patient department of Ningbo Yinzhou District Qianhu Hospital during Jan.-Dec. 2016 were divided into control group(69 cases) and observation group(70 cases)according to random number table. Control group was given Moxifloxacin hydrochloride tab-lets 0.4 g,po,qd;observation group was additionally given Montelukast sodium tablets 10 mg,po,once every night,on the basis of control group. Both groups were treated for 6 d. Cough symptom scores,peripheral blood WBC and CRP contents were compared between 2 groups before and after treatment. Clinical efficacies,the occurrence of ADR and clinical outcome were ob-served in 2 groups. RESULTS:Before treatment,there was no statistical significance in cough symptom scores,peripheral blood WBC or CRP contents between 2 groups(P>0.05). Compared to before treatment,cough symptom scores,peripheral blood WBC and CRP contents of 2 groups were decreased significantly after treatment,and the cough symptom score of observa-tion group after 3 d of treatment was significantly lower than that of control group at the same time,with statistical significance (P<0.05). There was no statistical significance in above indexes between 2 groups after 6 d of treatment(P>0.05). Cure rate of observation group was 64.29%,which was significantly higher than 44.93% of control group,with statistical significance (P<0.05). Response rates of observation group and control group were 97.14% and 97.10%,there was no statistical signifi-cance(P>0.05). No ADR was found in 2 groups during treatment,and good clinical outcome was obtained. CONCLUSIONS:Montlukast combined with moxifloxacin not only relieve cough symptom and inflammation,but also improve cure rate significantly with good safety.
ABSTRACT
Background and purpose:A pressing obstacle in clinical chemotherapy is drug resistance in breast cancer.A nano-delivery system,which has many advantages as a drug carrier,such as carrying anticancer drugs,can be used effectively to overcome drug resistance in tumors.This paper examined a new nano-delivery system,called calcium phosphate and glycerophosphocholine-mPEG(CAP/GPC-MPEG)composite nanoparticle and its influence on the cellular drug uptake of BCRP-over expressing mitoxantrone(MIT)-resistant breast cancer cell MCF-7/MIT.This paper will also examine its effect on overcoming drug resistance in the MCF-7/MIT cells.Methods:After the calcium phosphate and GPC-mPEG composite nanoparticles were designed and prepared,the entrapment efficiency and in vitro drug release of mitoxantrone-loaded nanoparticles were investigated.Quantitative comparisons were made between cellular uptake of drug-loaded nanoparticles and free drugs.Finally,a confocal laser scanning microscopy Was used to compare the subcellular distribution of drug-loaded nanoparticles and the free drugs.Results:Calcium phosphate and GPC-mPEG composite nanoparticles were nanoporous spherical particles with diameters between 50-100 mn.The MIT-loaded nanoparticles have an entrapment efficiency of(89.45±0.05)%.Although the drug-loaded nanoparticles showed an initial burst of drug release,it was followed by a more sustained release.The concentration of mitoxantrone was 1.89 times treated with MIT-loaded nanoparticles for 1 h compared to that treated with free mitoxantrone for 1 h in MCF-7/MIT cells.and which was 2.33 times in MCF-7 cells.Fluorescent red mitoxantrone appeared in the cytoplasm and nucleus of the MCF-7 and MCF-7,MIT cells treated with MlT-loaded nanoparticles whereas it is almost undetected in both cells treated with free mitoxantrone.Conclusion:Calcium phosphate and GPC-mPEG composite nanoparticles Can promote the cellular uptake and entering of mitoxantrone to the nucleus in MCF-7 and its corresponding BCRP-over expressing MIT-resistant MCF-7/MIT breast cancer cell lines.This nanoparticle is a potential nano-carrier for overcoming drug resistance in tumors.